LP-211是一种选择性的、可透过血脑屏障的5-HT7受体（Ki=0.58nM）激动剂，选择性高于5-HT1A受体（Ki=188nM）和D2受体（Ki=142nM）。
Cas No.:1052147-86-0
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
LP-211 is a selective, blood-brain barrier-permeable 5-HT7 receptor agonist (Ki=0.58nM) with higher selectivity over the 5-HT1A receptor (Ki=188nM) and the D2 receptor (Ki=142nM)[1-2]. LP-211 can modulate histone H3 acetylation levels and influence the association of the MeCP2 co-repressor protein by activating the 5-HT7 receptor. LP-211 can be used in research related to neurodevelopmental disorders such as Rett syndrome and Fragile X syndrome, as well as neuropathic pain and memory impairment[3-4].
In vitro, LP-211 (10µM) stimulated THP-1-derived macrophages for 48 hours. LP-211 significantly reduced the phagocytic and migratory capacity of pro-inflammatory M1-like macrophages, while also altering the cytokine and chemokine secretion profiles of all macrophage types (M0, M1, M2a, M2c)[5]. LP-211 (1µM) was incubated with mitochondria purified from human SH-SY5Y neuroblastoma cells for 3 minutes. LP-211 did not significantly affect the activity of mitochondrial respiratory chain cytochrome c oxidas[6].
In vivo, a single intraperitoneal injection of LP-211 (3mg/kg) was administered to male Fmr1-KO (B6.129P2-Fmr1tm1Cgr/J) mice, 30 minutes prior to behavioral testing. LP-211 significantly reduced the duration of their self-grooming behavior[7]. Single intraperitoneal injection of LP-211 (10mg/kg) was administered to adult male C57BL/6 mice 7-10 days after chronic constriction injury (CCI) surgery. The effects began 30 minutes post-injection and peaked between 90-150 minutes. LP-211 significantly increased the mechanical withdrawal threshold of the injured hind paw and completely blocked the place preference shift induced by noxious stimulation in the place escape/avoidance paradigm[8].
References:
[1] Leopoldo M, Lacivita E, De Giorgio P, et al. Structural modifications of N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides: influence on lipophilicity and 5-HT7 receptor activity. Part III. J Med Chem. 2008 Sep 25;51(18):5813-22.
[2] Beaudet G, Paizanis E, Zoratto F, et al. LP-211, a selective 5-HT7 receptor agonist, increases novelty-preference and promotes risk-prone behavior in rats. Synapse. 2017 Dec;71(12).
[3] Norouzi-Javidan A, Javanbakht J, Barati F, et al. Effect of 5-HT7 receptor agonist, LP-211, on micturition following spinal cord injury in male rats. Am J Transl Res. 2016 Jun 15;8(6):2525-33.
[4] Rahdar M, Davoudi S, Dehghan S, et al. Reversal of electrophysiological and behavioral deficits mediated by 5-HT7 receptor upregulation following LP-211 treatment in an autistic-like rat model induced by prenatal valproic acid exposure. Neuropharmacology. 2024 Oct 1;257:110057.
[5] Bahr FS, Müller FE, Kasten M, et al. Serotonin receptor 5-HT7 modulates inflammatory-associated functions of macrophages. Cell Mol Life Sci. 2025 Jan 21;82(1):51.
[6] Tempio A, Niso M, Laera L, et al. Mitochondrial Membranes of Human SH-SY5Y Neuroblastoma Cells Express Serotonin 5-HT7 Receptor. Int J Mol Sci. 2020 Dec 17;21(24):9629.
[7] Sharghi S, Flunkert S, Daurer M, et al. Evaluating the effect of R-Baclofen and LP-211 on autistic behavior of the BTBR and Fmr1-KO mouse models. Front Neurosci. 2023 Mar 30;17:1087788.
[8] Santello M, Bisco A, Nevian NE, et al. The brain-penetrant 5-HT7 receptor agonist LP-211 reduces the sensory and affective components of neuropathic pain. Neurobiol Dis. 2017 Oct;106:214-221.
LP-211是一种选择性的、可透过血脑屏障的5-HT7受体（Ki=0.58nM）激动剂，选择性高于5-HT1A受体（Ki=188nM）和D2受体（Ki=142nM）[1-2]。LP-211可通过激活5-HT7受体来调节组蛋白H3乙酰化水平并影响MeCP2共抑制蛋白的关联。LP-211可用于雷特综合征、脆性X综合征等神经发育障碍以及神经病理性疼痛和记忆障碍的相关研究[3-4]。
在体外，LP-211（10μM）刺激THP-1衍生的巨噬细胞48小时。LP-211可显著降低促炎性M1样巨噬细胞的吞噬能力和迁移能力，同时改变所有巨噬细胞类型（M0、M1、M2a、M2c）的细胞因子与趋化因子分泌特性[5]。LP-211（1μM）孵育从人SH-SY5Y神经母细胞瘤细胞中纯化的线粒体3分钟。LP-211对线粒体呼吸链细胞色素c氧化酶的活性无显著影响[6]。
在体内，LP-211（3mg/kg）在行为测试前30分钟对雄性Fmr1-KO（B6.129P2-Fmr1tm1Cgr/J）小鼠进行单次腹腔注射，可显著减少其自我梳理行为的持续时间[7]。LP-211（10mg/kg）对接受慢性坐骨神经压迫损伤（CCI）手术7-10天后的成年C57BL/6雄性小鼠进行单次腹腔注射，在注射后30分钟起效，并于90-150分钟达到峰值。LP-211可显著提高受伤后爪的机械撤退阈值，并完全阻断在位置逃避/回避范式中由伤害性刺激引起的位置偏好转换[8]。
| Cell experiment [1]: | |
Cell lines | THP-1-derived macrophages and human CD14+ cell-derived macrophages |
Preparation Method | THP-1 monocytes were differentiated into macrophages (M0, M1-like, M2a-like, M2c-like) using PMA and specific polarizing agents. Human CD14+ cells from PBMCs were differentiated into M1-like and M2-like macrophages using GM-CSF and M-CSF, respectively. Macrophages were stimulated with LP-211 (10μM) starting on day 3 or day 5 after seeding. |
Reaction Conditions | 10μM; 48 hours. |
Applications | LP-211 significantly reduced the phagocytic and migratory ability of pro-inflammatory M1-like macrophages. LP-211 treatment led to changes in the secretory properties (cytokine and chemokine profiles) of all macrophage types (M0, M1, M2a, M2c), with the highest effects observed for M0- and M2c-like macrophages. The importance of 5-HT7R for regulating phagocytosis was confirmed in human primary CD14+ cell-derived M2-like macrophages. |
| Animal experiment [2]: | |
Animal models | Male BTBR T+ Itpr3tf/J mice and male B6.129P2-Fmr1tm1Cgr/J (Fmr1-KO) mice |
Preparation Method | Animals received an acute intraperitoneal injection of LP-211 30 minutes prior to a series of behavioral tests performed starting at 5 weeks of age. Tests included the open field test, elevated plus maze (EPM), and self-grooming test. |
Dosage form | 3mg/kg; i.p.; single injection per test session. |
Applications | Acute LP-211 administration did not affect the behavioral abnormalities (anxiety, repetitive behavior) observed in BTBR mice. In Fmr1-KO mice, acute LP-211 treatment significantly improved repetitive behavior by reducing self-grooming duration and showed a trend to change anxiety levels, as evidenced by a decreased frequency of entries into the open arms of the EPM. |
References: | |
| Cas No. | 1052147-86-0 | SDF | |
| Canonical SMILES | O=C(NCC1=CC=C(C#N)C=C1)CCCCCN2CCN(C3=CC=CC=C3C4=CC=CC=C4)CC2 | ||
| 分子式 | C30H34N4O | 分子量 | 466.62 |
| 溶解度 | DMSO : ≥ 106.6 mg/mL (228.45 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.1431 mL | 10.7154 mL | 21.4307 mL |
| 5 mM | 428.6 μL | 2.1431 mL | 4.2861 mL |
| 10 mM | 214.3 μL | 1.0715 mL | 2.1431 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.50% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet